Argatroban in patients with acute ischemic stroke with early neurological deterioration: a cost-effectiveness analysis from the perspective of Chinese healthcare system
Argatroban is highly cost-effective for Chinese patients with AIS and END from the perspective of the Chinese healthcare system.
Authors
- Yake Lou (ORCID: https://orcid.org/0000-0002-2632-4412)
- Rong Su
- Xianbin Guo
- Ping Xu
- Li Wang (ORCID: https://orcid.org/0000-0003-1585-8846)
- Yan Liu (ORCID: https://orcid.org/0000-0001-7330-1793)
- Yu Xie (ORCID: https://orcid.org/0009-0003-4398-6607)
- Jie Tang (ORCID: https://orcid.org/0000-0001-8502-2855)
- Min Pan
- Ying Yu (ORCID: https://orcid.org/0000-0003-1472-7035)
- Qingtao Gong (ORCID: https://orcid.org/0009-0005-9452-0203)
- Liping Hu (ORCID: https://orcid.org/0000-0003-3946-2096)
- Junxiu Cai
Institutions
- Capital Medical University (CN)
- Beijing Tian Tan Hospital (CN)
- Beijing Anzhen Hospital (CN)
- Zigong First People's Hospital (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-04-03
- DOI
- https://doi.org/10.3389/fphar.2025.1470373
- Primary Topic
- Acute Ischemic Stroke Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00